Want to see IN:LOTUSEYE full AI Analyst Report?
Top Page
Lotus Eye Hospital And Institute Ltd
(LOTUSEYE)
Select Model
Select Model
Rating:44Neutral
Price Target:
₹110.00
▼(-6.86% Downside)
Action:Reiterated
Date:09/12/26
The score is primarily held back by weak financial performance—sharp margin deterioration, rising leverage, and deeply negative free cash flow—despite continued revenue growth. Technicals are broadly neutral with negative MACD and the price below key longer-term moving averages. Valuation is a major headwind due to an extremely high P/E and no dividend yield provided.
Positive Factors
Steady Revenue Growth
Steady revenue growth indicates continuing demand for the company’s ophthalmology consultations, diagnostics, and procedures. While growth is moderate, repeated top-line expansion supports the durability of its healthcare service model and provides a base for recovery if operating efficiency improves.
Negative Factors
Severe Margin Deterioration
Profitability has weakened to exceptionally thin net margins, while operating losses indicate that routine hospital activity is not currently covering operating costs. Unless margins recover, revenue growth may create little earnings benefit and leave less cash available for reinvestment or debt service.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Steady revenue growth indicates continuing demand for the company’s ophthalmology consultations, diagnostics, and procedures. While growth is moderate, repeated top-line expansion supports the durability of its healthcare service model and provides a base for recovery if operating efficiency improves.
Read all positive factors
Lotus Eye Hospital And Institute Ltd (LOTUSEYE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.36B
Dividend Yield0.59%
Average Volume (3M)1.55K
Price to Earnings (P/E)1448.6
Beta (1Y)0.88
Revenue Growth14.08%
EPS Growth-77.40%
CountryIN
Employees402
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.08
Shares Outstanding20,796,330
10 Day Avg. Volume1,141
30 Day Avg. Volume1,547
Financial Highlights & Ratios
PEG Ratio-27.83
Price to Book (P/B)3.28
Price to Sales (P/S)3.68
P/FCF Ratio-18.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lotus Eye Hospital And Institute Ltd Business Overview & Revenue Model
Company Description
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasi...
How the Company Makes Money
Lotus Eye Hospital And Institute Ltd primarily makes money by delivering paid eye-care services through its hospitals/centres. Key revenue streams typically include: (1) Clinical consultations and outpatient services (fees for specialist doctor vi...
Lotus Eye Hospital And Institute Ltd Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
58
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 572.54M | 537.14M | 495.63M | 482.10M | 470.44M | 389.10M |
| Gross Profit | 145.80M | 102.25M | 100.41M | 135.66M | 121.38M | 192.53M |
| EBITDA | 55.97M | 45.55M | 47.44M | 79.42M | 88.37M | 68.09M |
| Net Income | 1.49M | 804.00K | 7.39M | 29.14M | 40.77M | 29.84M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 825.97M | 695.74M | 666.27M | 631.88M | 615.97M |
| Cash, Cash Equivalents and Short-Term Investments | 38.27M | 37.26M | 39.78M | 69.30M | 83.31M | 87.93M |
| Total Debt | 0.00 | 158.34M | 34.30M | 11.10M | 11.04M | 12.38M |
| Total Liabilities | -601.38M | 224.60M | 95.73M | 72.17M | 56.09M | 69.88M |
| Stockholders Equity | 601.38M | 601.38M | 600.00M | 594.09M | 575.79M | 546.09M |
Cash Flow | ||||||
| Free Cash Flow | -2.68M | -106.28M | -21.25M | 403.00K | 12.90M | -2.73M |
| Operating Cash Flow | 5.09M | 24.15M | 27.02M | 56.83M | 43.87M | 44.12M |
| Investing Cash Flow | -4.83M | -125.78M | -43.50M | -46.33M | -21.94M | -39.35M |
| Financing Cash Flow | -9.27M | 98.39M | -12.42M | -34.02M | -17.05M | -15.75M |
Lotus Eye Hospital And Institute Ltd Technical Analysis
Negative
118.10
Price Trends
115.03
Negative
117.03
Negative
116.40
Negative
Market Momentum
0.14
Negative
49.02
Neutral
20.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LOTUSEYE, the sentiment is Negative. The current price of 118.1 is above the 20-day moving average (MA) of 112.31, above the 50-day MA of 115.03, and above the 200-day MA of 116.40, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 49.02 is Neutral, neither overbought nor oversold. The STOCH value of 20.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LOTUSEYE.
Lotus Eye Hospital And Institute Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹380.59B | 65.94 | ― | 0.07% | 21.27% | 4.09% | |
64 Neutral | ₹640.94B | 112.99 | ― | 0.58% | 15.70% | -2.76% | |
60 Neutral | ₹618.31B | 55.48 | ― | 0.13% | 17.50% | 20.65% | |
59 Neutral | ₹1.25T | 56.18 | ― | 0.25% | 17.20% | 32.79% | |
55 Neutral | ₹957.69B | 62.11 | ― | 0.22% | 15.96% | 26.87% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | ₹2.36B | 1,448.63 | ― | 0.59% | 14.08% | -77.40% |
* General Sector Average
IN:LOTUSEYE
Lotus Eye Hospital And Institute Ltd
116.00
-6.95
-5.65%
IN:APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,138.50
714.87
9.63%
IN:ASTERDM
Aster DM Healthcare Ltd.
695.60
64.65
10.25%
IN:FORTIS
Fortis Healthcare Ltd.
768.20
-220.25
-22.28%
IN:MAXHEALTH
Max Healthcare Institute Ltd
929.70
-180.88
-16.29%
IN:MEDANTA
Global Health Limited
1,364.55
58.71
4.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.